HC Wainwright & Co. Reiterates Buy on Oncternal Therapeutics, Maintains $19 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. has reiterated its Buy rating on Oncternal Therapeutics (NASDAQ:ONCT) and maintained a price target of $19.
July 16, 2024 | 11:53 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. has reiterated its Buy rating on Oncternal Therapeutics (NASDAQ:ONCT) and maintained a price target of $19.
The reiteration of a Buy rating and a maintained price target of $19 by HC Wainwright & Co. is a positive signal for investors, likely boosting short-term confidence and potentially driving the stock price up.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100